Table Of Content

INDEX TO VOLUME 87 Aalbers, R., B1, B3-7, B13-21, B23-24, B57-60 methotrexate, B57—-60 Abbott, J., 9-15 mild, 23—27, 439-444 Adam, K. A. R., 69-72 mortality, 183-186 Adenoidal bacteriology, 303-308 nedocromil sodium, 517-523 Adenosine 3’ 5’ cyclic monophosphate, 445-448 nocturnal, 581-585, B37—39 Aging lung; epidemiology, 5—7 occupational compensation, 569-570 B-Agonists and osteoporosis, A9-14 increasing doses, in chronic airflow limitation, 433-438 patients aged over 50 years, 517-523 Ahmed, T., 235 pulmonary rehabilitation, B41-44 AIDS, pneumothorax, 43-47, 400 respiratory arrests and salmeterol, 227-228, 638-639 Ainslie, G., 169-174 salbutamol, 23-27, 121-126, 636-638 Airway epithelial cells and inflammation, 406-408 salmeterol, 227-228, 439-444, 638-639 Airway mucins, 421-426 severe, 29-35, 139-143, B57—-60 Airway obstruction, mean transit time evaluation, 319 and social class, 139-143 Airways, effect of salbutamol, 23-27 sodium cromoglycate, 299-302, 517-523 Akkoclu, A., 397 stable, 439-444 Akpinar, O., 397 treatment development, B53—56 Alexander, M., 609-620 see also Childhood asthma; Chronic asthma Ali, J. M., 235 Atkinson, B., 551-553 Alkali nebulization and bronchostriction, 23 Aydilek, R., 635 Al Jarad, N., 309-312, 365-374 Ayres,J .G ., 183-186, 509-516, 517-523 Allen, M. B., 99-103 Allergic alveolitis; new insights, 495-501 Bacci, E., 121-126 Allergic bronchopulmonary aspergillosis, 237- Bacteriology of tonsil and adenoid, 303-308 Almitrine bismesylate, 93-98 Baigrie, R. J., 285-288 Alveolar volume, 1 15—120 Baldwin, D. R., 223-224, 595-601 Alveolitis, allergic; new insights, 495—S01 Balfour, T., 223-224 Alveolitis, fibrosing, 313-314 Balkanli, K., 635 Al-Sharif, A. F., 235 Ball, A. B. S., 147-148 Anderson, M. L. M., 413-420 Bambuiterol in nocturnal asthma, 581-585 Andrews, J. M., 595-601 Bancalari, L., 121-126 Andrews, S., 225-226 Barnes, N. C., 237, A20, A21, A26, A27-31, A35, A36, BS3-5S6 Androgens in bronchial carcinoma, 455-460 Bar-Yishay, E., 331-334 Antibiotics Bateman, E. D., 485-487 and acute exacerbations of bronchiectasis, 449-454 Beasley, R., 637 intravenous, in cystic fibrosis, 329-330 Beclomethasone dipropionate, 609-620 prescribing for cystic fibrosis, 535-539 in children, 445-448 Anti-neutrophil cytoplasmic antibodies, 240 Beech, C., 491-494 Arshad, H., 299-302 Benatar, S. R., 158 Arteriolar pulmonary resistance, 158 Berkman, N., 85-92, 571-579 Asbestos-related pericardial thickening detected by MRI, 309-312 Beveridge, C. J., 629 Asbestos workers, prognostic factors, 365-374 Bhatnagar, N. K., 489-490 Asbestosis Bilateral hilar enlargement with parenchymal homogeneous density, advanced, 115-120 635 measuring lung volumes, | 15—120 Black, D., 375-378 Ashour, M., 69-72, 400 Blair, I., 509-516 Assoufi, B. K., 587-593 Blood gas techniques, 79-80 Asthma Boldy, D. A. R., 517-523 acute, bronchial, 235 Bone marrow transplantation, pulmonary complications, 571-579 acute, severe, 29-35 Bone metabolism and corticosteroids, A33—36 alkali nebulization, 235 Bone physiology, A3—7 allergic, B3—7 Bone turnover bambuterol, 581-585 and corticosteroids, Al 5—21 beclomethasone dipropionate, 609-620 measurement methods, A9-14 bronchial, B13-—21 Workshop Review, Al—37 bronchial biopsies, B23—24 Bourke, S. J., 61-63 bronchial epithelial shedding, B9-11 Bouros, D., 351-358 bronchial hyperresponsiveness, 29-35, 133-138, 165-167, B3—7 Bowman, A., 455-460 bronchoconstriction, exercise-induced, 439-444 Boyd, G., Al, A20, A35, A36, A37 coping with, B67—70 Brear, S. G., 320 corticosteroids, 261-277, A23-26 Breathing, nasal, preferential, in adults, 295-297 early response, 121-126 Bremmer, P., 637 exercise-induced, 331-344 Breuer, R., 85-92, 571-579 fenoterol, 636-638 Bron, A. O., B37-39 fluticasone propionate, 609-620 Bronchial biopsies in asthma, B23—-24 hypothalamo-pituitary-adrenal axis suppression, 321 Bronchial carcinoma, 149-151, 455-460 immunohistology, B13-—21 Bronchial epithelial shedding, B9-11 and infection, 165-167 Bronchial hyperresponsiveness, 133-138 labelling shift from acute bronchitis, 183-186 allergic asthma, B3—7 leukotriene antagonist ONO-!078, 133-138 acute severe asthma, 29-35 methacholine, 23-27 in COPD, B3-7 ii Index direct and indirect, B31—36 Cholecystectomy, laparoscopic, in patients with cystic fibrosis, and infection, 165-167 today, B27-29 Chong, J. L., 285-288 Bronchial rupture, fibrin glue repair, 397 Chookang, J. Y., 581-585 Bronchiectasis Choudry, N. B., 29-35 acute exacerbations of, 449-54 Chronic airflow limitation, effect of f-agonists, 433-438 and antibiotics, 449-454 Chronic airflow limitation, stable, in elderly patients, 375-378 spirometric variables, 395-396 Chronic asthma Bronchoalveolar concentrations of ciprofloxacin and lomefloxacin and beclomethasone dipropionate, 445-448 following oral administration, 595-601 in children, 445-448 Bronchoalveolar lavage CsA, 319 in asbestos workers, 365-374 methotrexate 30 mg per week, 211-216 practical aspects, B25—26 nedocromil sodium, 238-239 Bronchoconstriction steroid-dependent, 211-216 and alkali nebulization, 235 Chronic obstructive pulmonary disease (COPD) fog-induced, 65-67 bronchial hyperresponsiveness, B3—7 in preterm infants, 37-42 inflammation, B3-7 and salmeterol, 439-444 and lung transplantation, B61—65 sodium cromoglycate protection, 37-42 nasal ventilation, 387-394 Bronchodilator therapy, response in young children born prema- nutritional depletion, B45-47 turely, 359-364 pulmonary rehabilitation, B41-44 Bronchodilator response to nebulized salbutamol in elderly patients, respiratory muscle function, B49-51 375-378 treatment development, B53—56 Bronchoscopy, fibre optic, 105-109 Chronic respiratory disease, nasal ventilation, 199-204 Brown, P., 321 Cimrin, A., 397 Brunet, F., 565-568 Ciprofloxacin Burge, P. S., 105-109, 509-516 in adult cystic fibrosis, 587-593 Burgess, C., 637 bronchoalveolar concentration, 595-601 Butler, J., 285-288 Clark, C. E., 227-228 Clark, F., 149-151 Clarke, K. W., 320 Cafferkey, M. T., 303-308 Clauvel, J. P., 559 Calderon, J., 158 Claydon, E., 43-47 Callol, L., 158 Clear-cell carcinoma oft he lung, 471-473 Campbell, I. A., 621-623 Coker, R. J., 43-47 Cancer Collins, J. V., 525-529 bronchial carcinoma, 455-460 Compensating occupational asthma, 569-570 intrathoracic tumours in children, 467-469 Computer system for a respiratory medicine department, 491-494 malignant mesothelioma ofp leura, 147-148 Conway, J. H., 387-394 pulmonary involvement in lymphoma, 85-92 Cook, D., 433-438 Capron, F., 229-230 Cordon, 8. M., 603-607 Capsaicin, cough induced by, in healthy volunteers, 379-382 Cornwell, W. E., 199-204 Carbon monoxide and exercise performance, 427-431 Coronary artery bypass surgery, 157 Carcinoma, bronchial, 149-151 Corris, P. A., 61-63 Cardiopulmonary bypass Corticosteroids inflammation and pentoxifylline, 285-288 in asthma, 261-277, A23-26 respiratory dysfunction following, 193-198, 557-558 effects on bone turnover (Workshop Review), Al-37 Carpenter, M. J., 509-516 and growth, A23-26 Carrara, M., 121-126 safety of, A27-31 Carroll, M. P., 387-394 and tuberculosis chemoprophylaxis, 485-487 Carswell, J. W., 398 Cortisol, 445-448 Carter, R., 193-198, 557 Coudere, L. J., 559 Cats, cough sounds, 49-54, 55-59 Cough Catterall, J. R., 1-3 capsaicin-induced, in healthy volunteers, 379-382 Caubarrere, I., 559 chronic, management, 249-251 Caul, E. O., 509-516 and lung oedema, 55-59 Cayton, R. M., 541-549 and simulated mucus, 49-54 CD, cell count, 153-155 sounds, in cats, 49-54, 55-59 Celik, M., 635 Coupland, B., 509-516 Chan, C. H. S., 383-385 s Crane, J., 637 Chemotherapy for lymph node tuberculosis, 621-623 Crompton, G. K., 321 Childhood asthma CsA, 319 fog-induced bronchoconstriction, 65-67 Cushing’s syndrome, 149-151 ipratropium bromide, 111-114 Cystic fibrosis nedocromil sodium, 65-67 adult, 9-15 terbutaline, 111-114 antibiotic prescribing practices, 535-539 Children endurance exercise capacity in adults, 541-549 born prematurely, bronchodilator therapy, 359-364 exercise training, B49-S1 chronic asthma and BDP, 445-448 intravenous antibiotics, 329-330 intrathoracic tumours in, 467-469 and laparoscopic cholecystectomy, 223-224 sodium cromoglycate, 299-302 nutrition, B49—51 spontaneous pneumothorax in, 531-534 oral ciprofloxacin, 587-593 Wright flow meter evaluation, 551-553 pre-death host inflammatory response, 603-607 Chillon, M. J., 158 Pseudomonas aeruginosa infection, 587-593 Index iii and Pseudomonas cepacia infection, 187-192 Fluticasone propionate, pressurized or dry powder, 609-620 S. newport in sputum, 625-627 Fog-induced bronchoconstriction, 65-67 spirometric variables, 395—396 Folgering, H., B41-44 Cytokines and the lung. Abstracts of 12th summer meeting of the Foster, C., 375-378 British Association for Lung Research, 641-656 Frankland, A. W., 551-553 Cytomegalovirus pneumonia, 345-349 Freeman, D. F., 303-308 Freeman, W., 541-549 D’Agay, M. F., 229-230 FrettsC.,, 5—7 Davidson, A. C., 237 Friend, J. A. R., 621-623 Davidson, K. G., 455-460 Frija, J., 229-230 Davies, M. J., 145-146 Fujimura, M., 133-138 Davies, R. J., 23-27, 165-167, 211-216, 405-408 Davies, R. J. O., 503-507 Gaffney, R. J., 303-308 Davis, A. M., 531-534 Gamsu, H. R., 217-221 Davison, J. R., 551-553 Gas exchange in liver cirrhosis, 93-98 Day, J., 609-620 Gaya, H., 187-192 de Boer, W. J., B61-65 Gazzard, B. G., 525-529 Deenen, Th. A. M., B67—70 Gellert, A. R., 365-374 Delamere, F. M., 603-607 Geraghty, R., 375-378 de Monchy, J. G. R., B23-24 Gerber, F., 229-230 Dente, F. L., 121-126 Giannini, D., 121-126 Desselberger, U., 509-516 GibsoG.n J,., 61-63, 149-151 Devalia, J. L., 405-408 Gibson, S. P., 105-109 Devlin, B., 61-63 Gill, M., 595-601 Dhainaut, J. F., 565-568 Giuntini, C., 121-126 Dhillon, D. P., 439-444 Glaucoma and nebulized bronchodilator therapy, 559-561 Di Franco, A., 121-126 Gleeson, M. J., 225-226 Diffuse panbronchiolitis; efficacy of erythromycin, 229-230 Godfrey, R. C., 387-394 Dilworth, P., 236 Godfrey,S. , 331-344 Dinsdale, D., 279-284 Goldstraw, P., 399 DNA amplification by PCR, 525-529 Gomez-Terreros, F. J., 158 Dodd, M., 9-15 Gonadotrophins in bronchial carcinoma, 455-460 Goodwin, A., 299-302 Earnshaw, J., 439-444 Grange, J. M., 398 Eastell, R., A13, Al4, A20, A26 Granuloma, plasma cell Eccles, R., 379-382 Gray, C. E., 455-460 Ectopic ACTH secretion, 149-161 Greening, A. P., 321 Edwards, A., 149-151 Greenough, A., 37-42, 111-114, 217-221, 359-364 Edwards, A. M., 239 Growth and corticosteroids, A23-26 Elborn, J. S., 603-607 Growth hormone, 445-448 Elderly patients with stable chronic airflow limitation; response to Guyatt,G . H., 433-438 salbutamol, 375-378 El-Din Hawass, N., 69-72 Haas, J. F., 636 El-Fiky, M. M., 193-198 Haddon, R., 433-438 Emphysematous disease, single lung transplantation for, 489-490 Haemodynamics in liver cirrhosis, 93-98 Endocrinopathies, respiratory muscles in, 351-358 Hall, D. R., 145-146 Eosinophilia, tropical, 17-21 Hamilton, P., 400 Epidemiology: the aging lung, 5—7 Hamilton-Wood, C., 471-473 Epidemiology of nocturnal asthma, B37-39 Hammond,J . M. J., 325-328 Epithelium, respiratory tract, and neoplasia, 175-181 Hara, N., 475-477 Erythromycin in diffuse panbronchiolitis, 229-230 Hardy,J . G., 461-465 Evans, A., 445-448 Harper, S., 433-438 Evans, M., 509-516 Harris, J. R. W., 43-47 Everett, L., 111-114 Hassan, W. U., 240, 581-585 Evrenoglou, D., 93-98 Hawker, J. 1., 509-516 Exercise endurance capacity in adults with cystic fibrosis, 541-549 Hayhurst, M. D., 161-163 Exercise-induced asthma, 331-344 Herbert, J., 609-620 Exercise performance, effect of carbon monoxide, 427-431 Heijerman, H. G. M., B49-51 Exercise performance, effect of nicotine, 427-431 Helium rebreathing, 115-120 Exercise training in cystic fibrosis, B49-51 Hematuria after respiratory tract infection, 73-74 Extracorporeal circulation for respiratory support in adults, 565-568 Henderson, A. F., 240 Herdman, M. J., 23-27 Faichney, A., 455-460 Herwaarden, C.v., B41-44 Family clusters of pulmonary tuberculosis in Japan, 205-209 Hide, D., 299-302 Farrell, I. D., 509-516 Hirano, H., 475-477 Feneck, R. O., 199-204 Hirsch, A., 229-230 Fenoterol, 636-638 Hitchcock, R. A., 387-394 Ferguson, A. D., 227-228 HIV Ferguson, H., 23-27 and lung limited lymphocytic proliferation, 559 Fibre optic bronchoscopy value audit in pneumonia, 105-109 and Pneumocystis carinii, 525-529 Fibrin glue repair of bronchial rupture, 397 Ho, J., 382-385 Fibrosing alveolitis, 313-314 Hodson, M. E., 187-192, 535-539, 587-593 Fitzgerald, M. J., 433-438 Holgate, S. T., B9-11 Flow meter evaluation in children and adults, 551-553 Holzer, R., 609-620 iv Index Honeybourne, D., 595-601 Leukotriene antagonist, ONO-1078, 133-138 Hosking, D. J., A13, Al4, A15—21, A35, A36 Leung, J.C. K., 383-385 Host inflammatory response, pre-death, in patients with cystic fibrosis Littlejohns, P., 139-143 and chronic P. aeruginosa infection, 603-607 Liver cirrhosis, 93-98 Hotta, I., 205-209 Lomefloxacin bronchoalveolar concentration, 595-601 Hough, A., 157 Lossos, I. S., 571-579 Howes, T., 236 Lundback, B., 609-620 Hudson, M., 320 Lung cancer Hughes. I., A35 bronchial carcinoma, 149-151 Hughes, J., A31 clear-cell carcinoma, 471-473 Hutchings, H. A., 379-382 communicating the diagnosis, 61-63 Hydatic cysts, 635 Cushing’s syndrome, 149-151 Hypercapnic respiratory failure, 409-41 | interleukin-2 receptors in, 383-385 Hypothalamo-pituitary-adrenal axis suppression, 321 oncogenes and onco-suppressor genes, 413-420 respiratory tract epithelium and neoplasia, 175-181 Immunohistology in bronchial asthma, B13-21 surgery, 383-385 Ind, P. W., 29-35, Al4, A31 in young patients of South India, 399 Infants, preterm Lung deposition from four nebulizers, 461-465 bronchoconstriction, 37-42 Lung limited lymphocytic proliferation in HIV, 559 sodium cromoglycate, 37-42 Lung oedema and cough sound creation, 55—S9 Inflammation Lung rest, 245-247 cardiopulmonary bypass, and pentoxifylline, 285-288 Lung and sleep, 503-507 mediators of, 405-408 Lung toxicology, 279-284 Ingram, C. G., 439-444 Lung transplantation and COPD, B61-65 Inhalational injuries caused by smoke and nitrogen dioxide, 169-174 Lung transplantation, single, for emphysematous disease, 489-490 Interleukin-2 receptors and lung cancer surgery, 383-385 Lung tumour, pulmonary sclerosing haemangioma, 475-477 Intestinal obstruction, 147-148 Luyt, D., 299-302 Intrapleural rupture of mediastinal teratoma, 69-72, 399 Lymph node tuberculosis, chemotherapy, 621-623 Intrathoracic tumours in children, 467-469 Lymphoma, pulmonary involvement, 85—92 Ip, M., 449-454 Ipratropium bromide in asthmatic children, 111-114 McCarty, M., 43-47 Iredale, M., 236 Macdonald, L. D., 139-143 Israel, H. L., 81-83, 153-155 Macfarlane, J. T., 289-294 McGlashan, J. A., 225-226 Jaeschke, R., 433-438 McHardy, G. J. R., 629 Jansen, H. M., B25—26 Mcllroy, W., 433-438 Jawad, M. S. M., 379-382 McNamee, C. J., 471-473 Jeffries, D. J., 525-529 McNicol, M. W., 427-431 Jenkins, P. A., 621-623 MaddisonJ.,, 9-15 Joharjy, I., 69-72 Magnetic resonance imaging detection of asbestos-related pericardial John, P. J., 395-396 thickening, 309-312 Jones, A., 299-302 Mahashur, A. A., 395-396 Jones, A. L., 609-620 Malo, J. L., 569-570 Joos, G. F., B31-36 Mannes, G. P. M., B61-65 Matsuda, T., 133-138 Kamio, Y., 133-138 Maule, B. H., 193-198 Kane, G. C., 153-155 Maxwell, D. L., 225-226 Kangro, H. O., 525-529 Mean transit time, 319 Karlikaya, C., 397 Mediastinal emphysema, 313-314 Kauffmann, F., 5-7 Mediastinal teratoma, 69-72, 399 Keogh, B. F., 245-247 Mediastinal teratoma rupture, 69-72 Kesten, S., 609-620 Meecham-Jones, J., 236 Kilburn, K. H., 115-120 Meijer, G. G., B37—-39 Kinnear, G., 65-67 Mesothelioma, malignant, of the pleura, 147-148 Kips,J .C ., B31-36 Methacholine, 23-27 Klip, E. C., B67-70 Methotrexate, 153-155, 211-216, BS7-60 Knoch, M., 461-465 Meuzelaar, J. J., B61—-65 Knox, A., 329-330 Meyns, B., 471-473 Knox, A. J., 223-224 Micro-organisms, defence against, 421-426 Kondo, T., 205-209 Miller, A., 115-120 Korpas, J., 49-54, 55-59 Miller, M. R., 319 Kudlicka, J., 55-59 Millhollon, B. W., 495-501 Kuipers, E. J., 73-74 Milner, A. D., 65-67 Kunter, E., 635 Mitchell, D., 43-47 Miyagawa, Y., 475-477 Lai, C. K. W., 383-385 Miyao, M., 205-209 Lai, K. N., 383-385 Montefort, S., B9-11 Lam, W. K., 449-454 Morgan, J. R., 320 LamblinG,. , 421-426 Morgan, M. D. L., 541-549 Lampropoulos, S., 93-98 Morris, D. J., 345-349 Langford, S. A., 99-103 Morris, J., 433-438 Lauder, I., 449-454 Morris, R. W., 551-553 Leigh, T. R., 525-529 Morris, S., 379-382 Leitch, A. G., 321, 629 Morrison, J. F., 581-585 Index y Moss, F., 43-47 Peckham, D., 329-330 Mucins, airway, 421-426 Pentoxifylline, cardiopulmonary bypass inflammation, 285-288 Mucus, simulated, 49-54 Pericardial thickening, asbestos-related; MRI detection, 309-312 Munro, N. C., 61-63, 400, 638 Peters, B., 43-47 Murray, M., 65-67 Peters, S. P., 153-155 Muscle function, B49-51 Petrie, G. R., 581-585 Muscles, respiratory, in endocrinopathies, 351—358 Phelan, P. D., 531-534 Pillai, R., 285-288 Nagata, N., 475-477 Plasma cell granuloma, Nakanishi, Y., 475-477 Plethysmography, | 15-120 Nakos, G., 93-98 Pleural effusions, 236-237 Nasa! breathing, preferential, in adults, 295-297 Pleural malignant mesothelioma, 147-148 Nasal ventilation in chronic obstructive pulmonary disease, 387-394 Pneumocystis carinii and HIV, 525-529 Nasal ventilation and chronic respiratory disease; weaning from Pneumomediastinum, 313-314 assisted ventilation, 199-204 Pneumonia Nebulized bronchodilator therapy causes acute closure glaucoma, audit of fibre optic bronchoscopy, 105-109 559-561 CD, cell count, 153-155 Nebulized sodium cromoglycate, 37-42 community acquired, 105-109, 289-294 Nebulizersj,et , salbutamol output from, 99-103 cytomegalovirus, 345-349 Nebulizer lung deposition, 461-465 methotrexate, 153-155 Nebulizer treatment, home, 157 Pneumocystis carinii, 153-155 Nedocromil sodium Pneumothorax in AIDS patients, 43-47, 400 in asthma patients aged over 50 years, 517-523 Pneumothorax, spontaneous, in paediatric patients, 531-534 in asthmatic children, 65-67 Postmus, P. E., 73-74 in chronic asthma, 238-239 Potgieter, P. D., 325-328 Neonatal surfactant replacement therapy, 217-221 Pozniak, A., 398 Neurilemoma, 145-146 Prescott, R. J., 621-623 Neurofibroma, 145-146 Prescribed respiratory diseases in the 1990s, 79 Newman, S. P., 465 Price, J. F., 111-114, A13, Al4, A23-26 Newnham, D. M., 439-444 Prior, A. J., 147-148 Newhouse, M., 433-438 Pseudomonas aeruginosa infection in cystic fibrosis patients, Nicholls, D. P., 295-297 587-593 Nicotine and exercise performance, 427-431 Pseudomonas aeruginosa infection, pre-death host inflammatory Nieman, R., 43-47 response, 603-607 Nikolaizik, W. H., 467-469 Pseudomonas cepacia pulmonary infection in cystic fibrosis patients, Ninan, T. K., 320 187-192 Ning, C. W. S., 581-585 Pulmonary complications of bone marrow transplantation, 571-579 Nitrogen dioxide, inhalational injuries, 169-174 Pulmonary function testing, preoperative, 161-163 Nocturnal asthma Pulmonary involvement in lymphoma, 85-92 epidemiology, B37—39 Pulmonary rehabilitation in asthma and COPD, B41-44 underlying mechanisms, B37—39 Pulmonary sclerosing haemangioma diagnosis, 475-477 Nocturnal respiratory research, 503-507 Pulmonary tuberculosis in Japan, 205-209 Nutrition in cystic fibrosis, B49—51 Nutritional depletion in COPD, B45—47 Q fever outbreak; clinical aspects, 509-516 O’Brien, C., 559-561 O’Connor, I., 313-314 O'Driscoll, B. R., 157 Radford, M., 445-448 Ohta, M., 475-477 Radiographic lung area, 115-120 Oncogenes in lung cancer, 413-420 Raine, R. I., 253-259 Onco-suppressor genes in lung cancer, 413-420 Ramsdale, H., 433-438 ONO-1078, 133-138 Reid, D. M., A9-14, A21, A26, A35, A36 Oosterhoff, Y., B37—39 Respiratory arrests in young asthmatics on salmeterol, 227-228, Or, R., 571-579 638-639 Oreffo, V. 1. C., 175-181 Respiratory dysfunction following cardiopulmonary bypass, OReilly, J. F., 581-585 193-198, 557-558 Ormerod, L. P., 127-131, 621-623 Respiratory failure, hypercapnic, 409-41 1 Osteoporosis Respiratory medicine department computer system, 491-494 and asthma, A9-14 Respiratory tract epithelium and neoplasia, 175-181 clinical evaluation of, A9-14 Respiratory tract infection, macroscopic hematuria after, 73-74 and corticosteroids, A9-14 Restrick, L. J., 199-204, 236 Osteoporotic process, A3—7 Richards, R. J., 175-181 Oto, O., 397 Rider, M. A., 555-556 Oxygen therapy, domiciliary, hazards of, 225-226 Rifampicin in steroid-dependent asthma, 629 Roche, W. R., B9-11 Paggiaro, P. L., 121-126 Rocker, G. M., 285-288 Pagliero, K. M., 471-473 Roe, S., 375-378 Palmer, J. B. D., 439-444 Rook, G. A. W., 398 Pantin, C. F. A., 491-494 Ross, B. A., 145-146 Parker, D., 285-288, 603-607 Roussel, P., 421-426 Patel, B., 239 Roussos, C., 409-411 Pauwels, R. A., B31-36 Rudd, R. M., 309-312, 365-374 Pearce, N., 637 Rupture, intrapleural, of mediastinal teratoma, 69-72 Pearson, S. B., 581-585 Russel, G., 320 vi Index Sahoo, R. C., 399 Taylor, I. K., 261-277 Sakakibara, H., 205-209 Taylor, R. F. H., 187-192, 535-539 Sakamoto, S., 133-138 *™T¢-DTPA clearance in asbestos workers, 365-374 Salbutamol, 636-638 Teratoma, mediastinal, 69—72, 399 controlled release; airway responsiveness, 23-27 Terbutaline in asthmatic children, 111-114 in elderly patients with stable chronic airflow limitation, 375-378 Testi, R., 121-126 mild asthma, 23-27 Thomas, G. O., 313-314 output from two jet nebulizers, 99-103 ThomaKs.,, 23-27 Salmeterol Thoracoscopy, 236-237 and bronchoconstriction, 439-444 Timens,W. , B13-21, B23-24 and respiratory arrests in young asthmatics, 227-228, 638-639 Timon, C. I., 303-308 Salmonella newport in cystic fibrosis, 625-627 Tong, P., 149-151 Salvaggio, J. E., 495-501 Tonsil bacteriology, 303-308 Sanderson, M., 236 Toxicology of the lung, 279-284 Saunders, K. B., 557 Tracheal tumours, rare, 145-146 Schols, A. M. W. J., B45-47 Transbronchial needle aspiration, 475-477 Scott, A. D., 199-204 TredaniJe.l, , 229-230 Scott, D., 400 Trigg, C. J., 23-27, 165-167, 211-216 Seaton, A., 237 Tropical eosinophilia, a review, 17-21 Selective decontamination, 325-328 Troshinsky, M. B., 153-155 Sell, L., 61-63 Tuberculosis Senior registrar appointments freeze, 236 acentury of, 158 Shale, D. J., 285-288, 603-607 chemoprophylaxis, 81—83, 398, 485-487 Shaw, R. J., 261-277 contact tracing (Blackburn 1982-90), 127-131 Sheldon, C. D., 237, 587-593 lymph node, 621-623 Shneerson, J. M., 581-585 puimonary; family clusters, 205—209 Shum, D., 449-454 Tumours Shunt fraction measurement, 193-198, 557-558 intrathoracic, in children, 467-469 Siafakas, N. M., 351-358 tracheal, rare, 145-146 Siddorn, J. A., 227-228 Turbitt, M. L., 581-585 Sim, K. M., 245-247 Turner, G., 400 Simpson, R. H. W., 471-473 Turner, J. A.M cM., 427-431 Singh, J., 559-561 Sleep apnoea and snoring, |—3 Ucan, E., 397, 635 Sleep and the lung, 503-507 Udwadia, F. E., 17-21 Sleep-related breathing disorders, 253-259 Udwadia, Z. F., 629 Smith, D. L., 509-516, 625-627 Underwood, S. R., 309-312 Smith, E. G., 509-516-625-627 Smith, M., B13-21 Smith, R., A3—7, Al4, A26, A31, A36 Vagaggini, B., 121-126 Smoke inhalational injuries, 169-174 van Aalderen, W. M. C., B37—39 Smoking, 157 van den Bosch, J. M. M., B25-26 Snead, D., 555-556 van der Bij, W., B61—65 Snoring and sleep apnoea, |-3 Van Uffelen, R., 609-620 So, S. Y., 449-454 Vassilakis, N., 93-98 Social class and severe asthma, 139-143 Ventilation, nasal Sodium cromoglycate in chronic obstructive pulmonary disease, 387-394 in asthma patients aged over 50 years, 517-523 in chronic respiratory disease, 199-204 in preterm infants, 37-42 VVirlalbeegca,s, MF.. ,R. , 1459-854 , 55-59 via inhaler and autohaler, 299-302 Soutar, C., 629 Vrugt, B., B3—7 Spandidos, D. A., 413-420 Spontaneous pneumomediastinum in patient with fibrosing alveolitis, Walker, C., B57-60 313-314 Walsh, M. A., 303-308 Sputum, inflammatory contents; effect of antibiotics, 449-454 Ward, A. K., 295-297 Sputum ofp atient with cystic fibrosis, S. newport in, 625-627 Ward, E. M., 199-204 Sridhar, G., 629 Ward, M. J., A33-36 Stableforth, D. E., 541-549, 625-627 Warner, J. O., 467-469 Stanford, C. A., 398 Warshaw, R. H., 115—120 Stanford, C. F., 295-297 Webb, A. K., 9-15 Stanford, J. L., 398 Wedzicha, J. A., 199-204 Staudinger, H. W., 636 Weir, D. C., 105—109 Sterk, P. J., B27-29 Wells, A., 239 Steroid-dependent asthma, 21 1—216, 629 Wensley, D. F., 531-534 Stockwell, M. C., 193-198 Westaby, S., 285-288 Stone, R., 249-251 Whallett, E. J., 183-186 Sullivan, R., 319 Wheatley, D. J., 193-198, 557 Surfactant replacement therapy, neonatal, 217-221 White, A., 149-151 Surgery, lung cancer, 383-385 White,J ., 149-151 Whyte, M. K. B., 29-35 Taggart, D. P., 193-198, 455-460 Widdicombe, J. G., 49-54, 55-59 Tang, C. M., 289-294 Wikeley, N. J., 239 Tang, O. T., 581-585 Willan, A., 433-438 Taskar, V. S., 395-396 Williams, I., 299-302 Index vii Winney, J. D. J., 103 Yagawa, K., 475-477 Winocour, P. H., 149-151 Yalcin, Z., 635 Wise, R., 595-601 Yamada, S., 205-209 Wood, A., 400 Yamanaka, K., 205—209 Wood, M. J., 509-516 Yntema, J. L., B57-60 Wood, P., 445-448 Yuksel, B., 37-42, 111-114, 217-221, 359-364 Wostenholme, R. J., 157 Wouters, E. F. M., B45-47 Zakynthinos, S., 409-411 Wright, M., 559-561 Zalcman, G., 229-230 Wright flow meter evaluation in children and adults, 551-553 Zeitlin, S., 445-448